US equities |
MU $989.04 ▼-3.88% META $742.96 ▲+3.38% NVDA $226.32 ▼-1.29% SNDK $1,487.33 ▼-5.97% SPCX $163.42 ▲+0.52% MSFT $541.15 ▲+1.14% AMD $594.24 ▼-2.28% AAPL $340.97 ▲+1.29%
FinancialContent

CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

5.190 -0.160 (-2.99%)
Delayed Quote Updated: 3:59 PM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CNS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
The Skull Could Be Playing an Immune System Role for the Brain
Via Investor Brand Network
NHS England Unveils Rapid Test for Brain Tumors
Via Investor Brand Network
Researchers in South Korea Identify New Protein That Controls Brain Cancer Growth
Via Investor Brand Network
Injectable Nanodevices Exhibit Potency Against Brain Tumors
Via Investor Brand Network
Accelerated Biological Aging Could Explain Why Younger Adults are Getting Cancer
Via Investor Brand Network
Laser Therapy Shows Promise in Treating Brain Cancer
Via Investor Brand Network
New T Cell Therapy Could Transform Glioblastoma Care
Via Investor Brand Network
Collagen Tiles Could Prevent Brain Cancer Recurrence
Via Investor Brand Network
Timing of Brain Metastasis Predicts Survival of Colorectal Cancer Patients
Via Investor Brand Network
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Business Development Strategy in Virtual Investor Segment
Via Investor Brand Network
News headline image
CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth
From CNS Pharmaceuticals, Inc.
Via ACCESS Newswire
Covid-19 Vaccine Could Extend Survival of Brain Cancer Patients
Via Investor Brand Network
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Strategic Transformation at Virtual Investor Conference
Via Investor Brand Network
News headline image
CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference
From CNS Pharmaceuticals, Inc.
Via ACCESS Newswire
Researchers Identify a Protein That Could Be Targeted in Glioblastoma Therapy
Via Investor Brand Network
NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 Results as Strategic Pivot Advances
Via Investor Brand Network
News headline image
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation
From CNS Pharmaceuticals, Inc.
Via ACCESS Newswire
Focused Ultrasound Shows Promise in Treating Brain Tumors
Via Investor Brand Network
Spanish Patient Highlights Risks of Poorly Cooked Pork
Via Investor Brand Network
Novel Vitamin B12 Treatment Offers Hope in Brain Cancer Treatment
Via Investor Brand Network
Experimental Immunotherapy Offers Hope Against Deadly Pediatric Brain Cancer
Via Investor Brand Network
Study Finds No Evidence That Mobile Phones Can Cause Brain Cancer
Via Investor Brand Network
Widely Prescribed Thyroid Hormone Could Prevent Pediatric Brain Tumor Recurrence
Via Investor Brand Network
New Vaccine Gives Brain Cancer Patients Hope of Longer Survival
Via Investor Brand Network
Scientists Find Targeting Enzyme That Could Block Brain Metastases
Via Investor Brand Network
WashU Vaccine Could Revolutionize Personalized Glioblastoma Treatment
Via Investor Brand Network
Study Links TBI to Higher Mortality Risk Due to Brain Cancer
Via Investor Brand Network
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Oversubscribed $22.5 Million Financing and Growth Strategy in Investor Presentation
Via Investor Brand Network
News headline image
CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment
Via ACCESS Newswire
Pediatric Brain Tumors Spread Faster as Immune Cells Build Enabling Scaffolding
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >